AI Just Beat Doctors at Diagnosing ER Patients. Don’t Get All Excited
Emergency departments and other clinical settings across the world are now one step closer to sounding like the…
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-)…
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks…
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development…
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker…
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety…